AbbVie inks deal with Parvus; Sofinnova invests in Cure51

20 Mar 2024

License out/inCell TherapyImmunotherapy

Plus, news about Aquestive Therapeutics and Cybin: AbbVie enlists Parvus Therapeutics for IBD pact: AbbVie will have the option to develop and commercialize Parvus’ therapies for inflammatory bowel diseases (IBD). Parvus’ therapies trigger T cells to grow and turn into regulatory T cells — a specialized type of T cell that can suppress the immune system. The deal adds another pipeline option to AbbVie’s IBD franchise, which includes Rinvoq and Skyrizi. And it adds to Parvus’ list of pharma collaborators, which include Novartis and Roche’s Genentech. Financial details of the licensing deal were not disclosed, though Parvus could receive a potential equity investment from AbbVie. — Lei Lei Wu

For more details,please visit the original website

The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.

Organizations

AbbVie, Inc.

Parvus Therapeutics IncSofinnova SARL

[+5]

Indications

Inflammatory Bowel Diseases

Targets

Drugs

UpadacitinibRisankizumab-RZAA

Hot reports

Global Drug R&D Express (Apr 2024)

PatSnap Synapse

Global Drug R&D Express (Mar 2024)

PatSnap Synapse

Global Drug R&D Express (Feb 2024)

PatSnap Synapse

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.